Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Serological markers for melanoma.

L Brochez¹, J M Naeyaert

¹Fund for Scientific Research Flanders, Egmontstraat 5, B-1000 Brussels, Belgium.

The British Journal of Dermatology

|August 22, 2000

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Health state utility instruments in patients with keratinocyte cancer and actinic keratosis: a cross-sectional study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022

Same author

Response to the Comment by Suijkerbuijk et al. 'Survival of stage IV melanoma in Belgium and the Netherlands'.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021

Same author

Incidence and survival of cutaneous melanoma in Belgium and the Netherlands from 2004 to 2016: striking differences and similarities of two neighbouring countries.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021

Same author

Lesion-directed screening to optimize skin cancer detection in dermatology practice: an observational study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021

Same author

Recommendations for skin cancer consultation and surgery during COVID-19 pandemic.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020

Same author

Chemoprevention of basal cell carcinoma: reply from authors.

The British journal of dermatology·2016

Serological markers show limited use in early melanoma detection but hold promise for predicting disease progression and therapy outcomes in advanced stages. Further research could guide personalized melanoma treatment strategies.

Area of Science:

Oncology
Immunology
Biochemistry

Background:

Serological markers are investigated for their role in melanoma patient management.
Current literature is reviewed to assess the significance of various biomarkers.

Purpose of the Study:

To evaluate the utility of diverse serological markers in melanoma.
To determine their potential in early detection, staging, prognosis, and therapy prediction.

Main Methods:

Literature review of studies on cytokines, S100 protein, melanoma inhibitory activity, and melanin metabolites.
Analysis of serum levels of various biomarkers in different stages of melanoma.

Main Results:

Most markers show increased levels in advanced melanoma, limiting early detection utility.

Related Experiment Videos

Sensitivity is <100% in advanced stages, restricting use as a definitive staging procedure.

Some markers show potential as prognostic factors for disease progression and therapy response.

Conclusions:

Serological markers are not suitable for early melanoma detection or definitive staging.
Promising prognostic value exists for predicting disease progression and treatment outcomes.
Future studies could refine therapeutic strategies and patient selection for adjuvant therapies.